Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the importance of understanding novel agents such as immunotherapeutic across disciplines in the treatment of genitourinary (GU) malignancies.

The rise of multidisciplinary care in GU malignancies means that it is no longer solely the job of the oncologists to administer novel agents such as immunotherapy.

Lallas says that this rise in multidisciplinary care, in addition to workforce shortages, means that it is very important for urologists and advanced practice providers to understand chemotherapy and immunotherapy regimens for GU malignancies.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Immunotherapy in GU Cancers

The OncLive Immunotherapy in GU Cancers condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in genitourinary malignancies, specifically prostate cancer, urothelial carcinoma, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Genitourinary Cancers

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research. 

Sidney Kimmel Cancer Center at Jefferson

Cancer Centers

Partner

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the importance of understanding novel agents such as immunotherapeutic across disciplines in the treatment of genitourinary malignancies.

Dr. Lallas on Understanding Immunotherapy in GU Malignancies